In cellular models of Parkinson’s disease with PRKN mutations, this compound restores mitophagy to near-normal levels while enhancing ubiquitination markers (TOM20, SYNJ2BP) and phosphoubiquitin accumulation. The gene discussed is PRKN; the disease is Parkinson disease.